Eevia Health Plc (”Eevia” or “the Company”) announced on Tuesday, March 19th, that the Company has received a grant of approx. SEK 2.7m (EUR 243k) from Business Finland for finalizing a development project for the documentation of bioactivity on Eevia’s products. Eevia executed the project in 2023 and submitted the final report in Q1-24, which has now been approved.

Länk till analysen